Clinical pharmacology research for promoting individualized cancer chemotherapy

Hiroyuki Watanabe, Mayako Uchida, Satohiro Masuda

研究成果: ジャーナルへの寄稿総説査読

1 被引用数 (Scopus)


Cancer chemotherapy has progressed remarkably with conventional and molecular-targeted anticancer drugs as well as immune checkpoint inhibitors. However, adverse drug reaction (ADR) management remains a challenge in cancer chemotherapy. Therefore, improving the quality of medical care through clinical pharmacology research is warranted. Intravenous injection of bendamustine in patients with follicular or mantle cell lymphoma frequently causes venous irritation. Because the underlying mechanisms are not clear, we investigated the factors responsible for bendamustine-induced venous irritation. Based on the results of our analysis, we altered the administration regimen and observed that the incidence of venous irritation, which manifested in a concentration-dependent manner following conventional approaches, significantly decreased when following the modified regimen. Guidelines on the management of chemotherapy-induced nausea and vomiting recommend aprepitant, a selective neurokinin-1 (NK-1) receptor antagonist, 5-hydroxytryptamine 3 (5-HT3) receptor antagonists, and dexamethasone as prophylactic antiemetics. Pretreatment with high-dose chemotherapy before hematopoietic stem cell transplantation has extremely high emetogenic potential. This can be countered by using aprepitant in combination with conventional antiemetics. However, the safety and e‹cacy of such combinations are unexplored. Upon evaluation, we observed improved antiemetic effects without an increase in ADRs. At this symposium, I highlight the significance of clinical pharmacology research for promoting individualized cancer chemotherapy.

ジャーナルYakugaku Zasshi
出版ステータス出版済み - 2019

!!!All Science Journal Classification (ASJC) codes

  • 薬理学
  • 薬科学


「Clinical pharmacology research for promoting individualized cancer chemotherapy」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。